RedHill Biopharma Shares Trading Higher On Improved Q1 Profitability

  • RedHill Biopharma Ltd RDHL plans announced a cost reduction plan expected to generate operational cost savings of approximately $50 million over the next 18 months.
  • Most of these savings result from an approximately one-third reduction of the U.S. commercial team workforce, streamlined operational expenditure, including SG&A expenses, and refining the company's R&D strategy to rely mostly on external funding sources. 
  • Q1 FY22 net revenues reached $18.2 million, down from $20.5 million a year ago, attributable to typical cyclical trends in Movantik sales and increased gross to net deductions related mainly to increased formulary coverage.
  • Gross margins improved from 50.2% to 55.9%
  • The company reported a narrower operating loss of $(13.2) million compared to $(18.1) million a year ago.
  • Net loss came in at $(17.1) million compared to $(22.8) million a year ago.
  • Price Action: RDHL shares are up 2.02% at $0.78 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!